Former pharmaceutical CEO Martin Shkreli goes on trial starting Monday for federal securities fraud. Shkreli, who became known as “pharma bro,” came under widespread criticism for upping the price of the lifesaving drug Daraprim 5,000 percent. He is going on trial for something unrelated — prosecutors say that he operated a Ponzi-like scheme at two companies he ran.

Here & Now‘s Jeremy Hobson speaks with MSNBC’s Ali Velshi (@AliVelshi) about what’s expected in the trial.

Copyright 2017 NPR. To see more, visit http://www.npr.org/.

300x250 Ad

Support quality journalism, like the story above, with your gift right now.

Donate